Ir al contenido

Medicine Access and Effective Coverage in a Fragmented Health System, Mechanisms and Policy Implications

Achieving equitable access to essential pharmaceutical treatments represents a cornerstone of universal health coverage within structurally divided delivery networks. Fragmented health systems generate systemic inefficiencies, compounding pricing barriers, regulatory inconsistencies, and uneven supply chain distribution. Addressing these structural deficits requires multilevel governance reforms, unified pricing mechanisms, and integrated delivery frameworks to secure comprehensive therapeutic coverage.

Objetivo

To evaluate how governance, pricing, and supply mechanisms in fragmented health systems influence medicine access and effective coverage.

Metodología

Desk-based comparative policy analysis synthesizing peer-reviewed health systems literature and institutional pharmaceutical frameworks.

Novedad científica

Integrates supply chain governance, price regulation, and delivery fragmentation into a unified analytical model for pharmaceutical access.

Vista previa del documento

Esta es una vista previa breve. La versión completa incluye texto ampliado para todas las secciones, una conclusión y una bibliografía formateada.

Scientific Article

Degree:
Medicine Access and Effective Coverage in a Fragmented Health System, Mechanisms and Policy Implications

Author:

Group

First M. Last

Advisor:

Dr. First Last

City, 2026

Contents

Abstract
Introduction
Theoretical Dimensions of Health System Fragmentation and Drug Distribution
Methodological Framework for Comparative Policy Synthesis
Supply Chain Governance and Local Production Dynamics
Pricing Regulations, Intellectual Property, and Cost Containment
Discussion: System Integration and Effective Therapeutic Coverage
Policy Recommendations for Resilient Pharmaceutical Systems
Conclusion
Bibliography

Introduction

Ensuring universal access to essential pharmaceuticals remains a defining benchmark of robust healthcare systems worldwide. Structural fragmentation across public and private delivery channels frequently compromises pharmaceutical supply chains, which intensifies the proliferation of substandard medications and undermines clinical trust across vulnerable populations [1].

Disparities in regulatory oversight and decentralized procurement structures exacerbate financial burdens and create severe geographic variations in medicine availability. When health systems lack coordinated technology assessment and centralized price negotiation, institutional coverage gaps widen, preventing systematic delivery of essential therapeutic regimens to patients [2], [3].

Evaluating institutional mechanisms across disparate policy models reveals the critical levers necessary to bridge delivery divides and enhance therapeutic adherence. Aligning regulatory harmonization, strategic local manufacturing initiatives, and transparent pricing controls constitutes an indispensable operational strategy for transforming fragmented health infrastructures into integrated, equitable delivery platforms [1], [5].

Discussion: System Integration and Effective Therapeutic Coverage

The structural fragmentation of pharmaceutical delivery channels severely impairs therapeutic coverage by generating disparities in supply security and regulatory oversight. Achieving equitable access across divided healthcare sectors demands synchronized policy instruments that link local production capabilities with robust pricing and quality frameworks. As demonstrated in broader health system analyses, supply chain vulnerability and the prevalence of substandard pharmaceutical products threaten therapeutic safety, necessitating a systemwide, multilevel approach to strengthen domestic manufacturing and regulatory control (Advancing Health System Strengthening Through Improving Access to Medicines, 2020). When decentralized procurement systems operate without harmonized standards, institutional trust deteriorates and patients encounter severe financial burdens. Conversely, targeted price regulation and coordinated priority listings demonstrate how systemic interventions improve pharmaceutical affordability and distribution continuity within public delivery tiers (Patient Experiences of Access to NCD Medicines in Sri Lanka, 2019). When prescribers align therapeutic decisions with regulated essential lists, availability improves across public facilities, mitigating reliance on fragmented private markets. Furthermore, cross-jurisdictional collaboration on health technology assessments and intellectual property governance highlights the necessity of collective bargaining and institutional coordination to resolve access bottlenecks (The Top 5 Issues in EU Medicines Policy for 2018, 2018). Ultimately, addressing pharmaceutical fragmentation requires moving beyond isolated sectoral procurement toward unified governance models. By integrating multilevel regulatory enforcement, domestic manufacturing initiatives, and coordinated price controls, health systems can systematically expand effective coverage and protect vulnerable populations from therapeutic exclusion.

References

  1. Advancing health system strengthening through improving access to medicines: A review of local manufacturing policies in Ghana
    Kwame Peprah Boaitey, Chloe Tuck
    Enlace DOI
  2. Health policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countries
    Maryam Bigdeli, Dena Javadi, Joelle Hoebert et al.
    Enlace DOI
  3. The top 5 issues in EU medicines policy for 2018
    Yannis Natsis
    Enlace DOI
  4. Framing access to medicines in developing countries: an analysis of media coverage of Canada's Access to Medicines Regime
    Laura C Esmail, Kaye Phillips, Victoria Kuek et al.
  5. Patient experiences of access to NCD medicines in Sri Lanka: Evidence of the success story towards universal coverage
    BMR Fernandopulle, Nalika Gunawardena, SHP de Silva et al.
  6. Intellectual Property and Access to Medicines: Paradoxes in Moroccan Policy
    Gaelle Krikorian

Bibliografía

Fuentes VerificadasNormas de FormatoAlta OriginalidadModelos Pro
🔥 25% OFF

Artículo

APA 7ª Edición (con adaptación "y otros")

US$ 7US$ 9
  • 8–20 páginas
  • Alta originalidad
  • Exportar a Word
  • Formato correcto
  • Vista previa pública
    La vista previa de otro autor no puede hacerse privada. Tu trabajo será privado y completamente único.
  • Bibliografía (20+, APA 7ª Edición)
    +US$ 2
  • Añadir fuentes alternativas (Noticias, .gov, .edu)

Artículo

APA 7ª Edición (con adaptación "y otros")

Medicine Access and Effective Coverage in a Fragmented Health System, Mechanisms and Policy Implications | Artículo | Aicademy